Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Madrigal Pharmaceuticals Inc
Net Issuance of Common Stock
Madrigal Pharmaceuticals Inc
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
Net Issuance of Common Stock
$735.1m
|
CAGR 3-Years
63%
|
CAGR 5-Years
398%
|
CAGR 10-Years
23%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Issuance of Common Stock
-$1.5B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-13%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Issuance of Common Stock
-$728m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
14%
|
CAGR 10-Years
18%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Issuance of Common Stock
-$200m
|
CAGR 3-Years
66%
|
CAGR 5-Years
52%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Issuance of Common Stock
-$1.1B
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Issuance of Common Stock
-$1.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-78%
|
CAGR 10-Years
N/A
|
|
Madrigal Pharmaceuticals Inc
Glance View
In the competitive and complex landscape of pharmaceuticals, Madrigal Pharmaceuticals Inc. has carved a niche for itself by focusing on the development of innovative therapies for metabolic and liver diseases. Founded with the visionary zeal to address unmet medical needs, Madrigal's journey is grounded in its dedication to advancing science and transforming patient care. The company's primary research and development efforts center around addressing non-alcoholic steatohepatitis (NASH), a significant liver condition that lacks approved treatments. With a keen eye on scientific innovation, Madrigal invests heavily in creating solutions for conditions that are not only challenging but also growing in prevalence, thus embodying the dual mission of driving better health outcomes and capturing market opportunities. Madrigal's business model is largely reliant on the successful progression of its lead candidate, resmetirom, through clinical trials and regulatory approval processes. This strategy, typical in the pharmaceutical arena, involves rigorous stages of testing to ensure efficacy and safety, aiming to bring the drug to market where it can address the substantial need. Revenue generation for Madrigal is intrinsically linked to licensing agreements, strategic partnerships, and eventual drug sales post-approval. This approach necessitates significant initial investment and patience, with the expectation of substantial returns contingent upon successful product commercialization. Through this focus, Madrigal advances towards not only improving the therapeutic landscape for liver diseases but also carving out a significant presence in the biotech market.
See Also
What is Madrigal Pharmaceuticals Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
735.1m
USD
Based on the financial report for Dec 31, 2024, Madrigal Pharmaceuticals Inc's Net Issuance of Common Stock amounts to 735.1m USD.
What is Madrigal Pharmaceuticals Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 10Y
23%
Over the last year, the Net Issuance of Common Stock growth was 39%. The average annual Net Issuance of Common Stock growth rates for Madrigal Pharmaceuticals Inc have been 63% over the past three years , 398% over the past five years , and 23% over the past ten years .
You don't have any saved screeners yet